Media Articles Related to Revatio (Sildenafil)
FDA Warns About Sildenafil in Kids with PAH
Source: MedPage Today Product Alert [2012.08.31]
The FDA has cautioned against using sildenafil (Revatio) to treat pulmonary arterial hypertension in children younger than 17, after an unexpectedly high rate of mortality in a clinical trial.
Menstrual cramping may be alleviated by vaginally administered sildenafil citrate
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2013.12.09]
Women with moderate to severe menstrual cramps may find relief in a class of erectile dysfunction drugs, according to a team of researchers led by Penn State College of Medicines Richard Legro.
Sildenafil Helps Turn 'Bad' White Adipose Tissue Into 'Good And Healthy' Brown Adipose Tissue
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2013.04.03]
Although sildenafil is best known for promoting erections, it may also serve as a weight loss aid by coaxing our bodies to store more healthy "brown fat" relative to unhealthy "white fat" than it...
Around two thirds of Viagra consumed in the Netherlands may be illegal, warn Dutch experts
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2014.07.03]
At least two-thirds of the erectile dysfunction drug sildenafil (e.g. Viagra) consumed in the Netherlands may be illegal, warn researchers today.In a letter published on bmj.
Duchenne muscular dystrophy may be treated with erectile dysfunction drug
Source: Muscular Dystrophy / ALS News From Medical News Today [2014.05.08]
Drugs commonly used to treat erectile dysfunction and pulmonary arterial hypertension - sildenafil and tadalafil - could help treat Duchenne muscular dystrophy, a new study finds.
Published Studies Related to Revatio (Sildenafil)
The effect of sildenafil on respiratory weaning of patients with chronic
obstructive pulmonary diseases admitted to intensive care unit. 
facilitating the weaning of COPD patients from the ventilator... CONCLUSION: Sildenafil facilitated weaning of COPD patients from the ventilator
Sildenafil for chronic obstructive pulmonary disease: a randomized crossover
exercise capacity in patients with COPD and emphysema... CONCLUSIONS: Routine sildenafil administration did not have a beneficial effect
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children with Pulmonary Arterial Hypertension. [2011.11.29]
CONCLUSIONS: Sixteen-week sildenafil monotherapy is well tolerated in pediatric PAH. Percentage change in pVO(2) for the three sildenafil doses combined was only marginally significant; however, pVO(2), FC, and hemodynamic improvements with medium and high doses suggest efficacy with these doses. Combined with STARTS-2 data, the overall profile favors the medium dose. Further investigation is warranted to determine optimal dosing based on age and weight. CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov; NCT00159874.
Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. [2011.11.07]
CONCLUSIONS: PDE5 inhibition in HF patients with EOB offers the dual advantage of improving functional capacity and modulating the EOB pattern. PAP and PVR reduction seem to underlie the correction of the breathing disorder. Whether reversal of this unfavourable prognostic signal can affect survival remains unconfirmed at the moment.
Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension: The SUPER-2 Study. [2011.11]
BACKGROUND: The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed... CONCLUSIONS: Long-term treatment of PAH initiated as sildenafil monotherapy was generally well tolerated. After 3 years, the majority of patients (60%) who entered the SUPER-1 trial improved or maintained their functional status, and 46% maintained or improved 6MWD. Trial registry: ClinicalTrials.gov; No.: NCT00159887; URL: www.clinicaltrials.gov.
Clinical Trials Related to Revatio (Sildenafil)
A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes [Completed]
To determine the effect on erectile function in a population of type 2 diabetic men with
erectile dysfunction who have undergone the following treatment regimen: pre-treatment with a
daily dose of double-blind sildenafil versus placebo for 4 weeks (Phase I) followed by an
as-needed, flexible-dose, open-label treatment phase with sildenafil for 12 weeks (Phase II).
To assess safety and tolerability of this dosing regimen and to investigate its effects on
endothelial function and subject's responses to the Self-Esteem And Relationship (SEAR)
A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia [Completed]
The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of
sildenafil 50 & 100 mg added to stable antipsychotic treatment in schizophrenia patients to
assess whether this PDE5 inhibitor improves cognitive functioning (including verbal memory,
fluency, attention, spatial memory, motor speed, and executive function) and clinical
symptoms (psychotic, negative, mood symptoms, and self-reports of side-effects).
Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke [Recruiting]
Stroke is the third leading cause of death in the United States and the leading cause of
serious long-term disability. Approximately 50% of the 750,000 people affected by stroke
each year have residual physical impairment. Treatment options for recovery are limited at
this time. Sildenafil (Viagra) has demonstrated the capability of significantly improving
recovery in several animal experiments of stroke. This study is aiming to establish the
safety of treatment with sildenafil in people with stroke with the ultimate aim of testing
its usefulness to improve recovery.
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy [Recruiting]
This study, supported by Charley's Fund, Inc., is being done to determine if the drug
RevatioŽ(also known as Sildenafil), as compared to placebo (an inactive substance that looks
like the study drug, but contains no medication), improves heart function in people with
Duchenne Muscular Dystrophy and Becker Muscular Dystrophy (DBMD).
In people with DBMD, dystrophin is not present or lacking in heart and muscle. This is
associated with abnormalities in an enzyme called "neuronal nitric oxide synthase" or nNOS,
and leads to decreases in "cyclic GMP," which is necessary for proper function of those
muscles. Revatio blocks an enzyme called phosphodiesterase 5 (PDE5), and helps to restore
the normal amounts of cyclic GMP. The purpose of this research is to determine if Revatio
is safe for people with DBMD and if it can improve heart function.
Hypothesis : PDE5 inhibition, with the use of Revatio, will improve cardiac function in
patients with DBMD.
Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients [Recruiting]
This pilot study is aimed at assessing the short-term effects of Tadalafil on the
hemodynamic response to exercise and exercise capacity in patients with Fontan circulation.
Data regarding effect size and drug tolerability will be used in the design of a randomized
multicenter trial. The long-term goal of this investigation is to systematically evaluate
the effect of tadalafil therapy on exercise performance, quality of life, and delay of
functional deterioration in patients with single ventricle physiology.
Reports of Suspected Revatio (Sildenafil) Side Effects
Pulmonary Hypertension (93),
Disease Progression (52),
Cardiac Failure (44),
Dizziness (38), more >>